{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:26Z","timestamp":1789015646432,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"honoraria from Roche, Takeda and MSD; consulting or advisory role for Amgen, Pfizer, Takeda, MSD; research funding from Novartis, MSD, Takeda; travel funding from MSD, Takeda, Novartis."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41375-019-0609-3","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T13:12:42Z","timestamp":1571663562000},"page":"953-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group"],"prefix":"10.1038","volume":"34","author":[{"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Pl\u00fctschow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-1091","authenticated-orcid":false,"given":"Sylvia","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin-Leo","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/asheducation-2017.1.324","volume":"2017","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematol Am Soc Hematol Educ Program. 2017;2017:324\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","volume":"118","author":"DA Eichenauer","year":"2011","unstructured":"Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Boll B, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118:4363\u20135.","journal-title":"Blood"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","volume":"32","author":"RH Advani","year":"2014","unstructured":"Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32:912\u20138.","journal-title":"J Clin Oncol"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","volume":"111","author":"H Schulz","year":"2008","unstructured":"Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109\u201311.","journal-title":"Blood"},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/leu.2015.321","volume":"30","author":"DA Eichenauer","year":"2016","unstructured":"Eichenauer DA, Goergen H, Plutschow A, Wongso D, Behringer K, Kreissl S, et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia. 2016;30:1425\u20137.","journal-title":"Leukemia"},{"key":"609_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","volume":"27","author":"Z Fan","year":"2003","unstructured":"Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346\u201356.","journal-title":"Am J Surg Pathol"},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","volume":"122","author":"S Hartmann","year":"2013","unstructured":"Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;122:4246\u201352. quiz 4292.","journal-title":"Blood"},{"key":"609_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.13540","volume":"171","author":"AG Shankar","year":"2015","unstructured":"Shankar AG, Kirkwood AA, Hall GW, Hayward J, O\u2019Hare P, Ramsay AD. Childhood and adolescent nodular lymphocyte predominant Hodgkin lymphoma\u2014a review of clinical outcome based on the histological variants. Br J Haematol. 2015;171:254\u201362.","journal-title":"Br J Haematol"},{"key":"609_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","volume":"130","author":"MA Fanale","year":"2017","unstructured":"Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017;130:472\u20137.","journal-title":"Blood"},{"key":"609_CR10","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","volume":"33","author":"DA Eichenauer","year":"2015","unstructured":"Eichenauer DA, Plutschow A, Fuchs M, von Tresckow B, Boll B, Behringer K, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015;33:2857\u201362.","journal-title":"J Clin Oncol"},{"key":"609_CR11","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","volume":"133","author":"S Borchmann","year":"2019","unstructured":"Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019;133:2121\u20139.","journal-title":"Blood"},{"key":"609_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","volume":"132","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Plutschow A, Schroder L, Fuchs M, Boll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132:1519\u201325.","journal-title":"Blood"},{"key":"609_CR13","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","volume":"123","author":"KH Xing","year":"2014","unstructured":"Xing KH, Connors JM, Lai A, Al-Mansour M, Sehn LH, Villa D, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014;123:3567\u201373.","journal-title":"Blood"},{"key":"609_CR14","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","volume":"118","author":"KJ Savage","year":"2011","unstructured":"Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118:4585\u201390.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0609-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:23Z","timestamp":1684618703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0609-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0609-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BvT: honoraria from Roche, Takeda and MSD; consulting or advisory role for Amgen, Pfizer, Takeda, MSD; research funding from Novartis, MSD, Takeda; travel funding from MSD, Takeda, Novartis. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}